TY - JOUR
T1 - Neuropathological features of a case with schizophrenia and prion protein gene P102L mutation before onset of Gerstmann-Sträussler-Scheinker disease
AU - Sasaki, Kensuke
AU - Doh-Ura, Katsumi
AU - Furuta, Akiko
AU - Nakashima, Sachi
AU - Morisada, Yumi
AU - Tateishi, Jun
AU - Iwaki, Toru
N1 - Funding Information:
Acknowledgements We thank Ms. K. Hatanaka for her excellent technical assistance. This study was supported partly by a grant to Dr. K. Doh-ura from the Ministry of Health, Labour and Welfare, Japan. Part of this study was carried out at the Morphology Core, Graduate School of Medical Sciences, Kyushu University. The English used in this manuscript was revised by Miss K. Miller (Royal English Language Centre, Fukuoka, Japan).
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Gerstmann-Sträussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.
AB - Gerstmann-Sträussler-Schein ker disease (GSS) is a hereditary transmissible spongiform encephalopathy associated with prion protein gene mutation P102L. The age of onset is roughly restricted to around the sixth decade; however, it is unclear whether the disease-specific pathology of GSS is already evident in the pre-clinical stage. We had a chance to examine an autopsy case with PRNP P102L mutation. The patient had died at 50 years of age before the clinical symptoms of GSS had appeared; neither neuronal loss, gliosis nor spongiform change was found anywhere in the brain. Immunohistochemistry failed to detect any deposition of prion protein. It is thus considered that amyloid plaque formation in GSS probably develops in a relatively rapid fashion compared with Alzheimer's disease. Although the patient suffered from schizophrenia, no significant pathological changes were detected except for astrocytic inclusion bodies in the cerebral cortex. The nature and significance of the inclusion bodies, which are not observed in patients with GSS, remain unclear.
UR - http://www.scopus.com/inward/record.url?scp=0038082169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038082169&partnerID=8YFLogxK
U2 - 10.1007/s00401-003-0697-y
DO - 10.1007/s00401-003-0697-y
M3 - Article
C2 - 12682740
AN - SCOPUS:0038082169
SN - 0001-6322
VL - 106
SP - 92
EP - 96
JO - Acta neuropathologica
JF - Acta neuropathologica
IS - 1
ER -